The University of Minnesota Cancer Center (UMCC) is a NCI-designated Comprehensive Cancer Center dedicated to cancer research, education, and patient care for the citizens of the state of Minnesota and surrounding region. Since the time of the first award in 1997, there has been tremendous growth of the membership and research base. In 2007 we have 225 members with nationally peer-reviewed support totaling over $95 million. This compares to 151 members and $70 million in 2002 and 98 members and $39 million in 1997. Thus, in 10 years, the UMCC has more than doubled our membership and peer-reviewed research base. The mission of UMCC is: to create a collaborative environment that advances knowledge about the causes, prevention, detection, and treatment of cancer;to apply that knowledge to caring for our patients;and to share our discoveries with other scientists, students, professionals, and the community. To achieve these goals the Cancer Center membership is organized into seven programs: Prevention and Etiology, Carcinogenesis and Chemoprevention, Genetic Mechanisms of Cancer, Tumor Biology and Progression, Immunology, Women's Cancer, and Transplant Biology and Therapy. Ten shared resources support this research. During the last period of support, a new UMCC Director was named and changes in the administrative structure were created to facilitate the research of its members, to foster multidisciplinary approaches to cancer, to provide infrastructure support for the conduct of cancer research, and to lead in the creation of new methods and strategies to reduce cancer incidence and mortality. The Academic Health Center and the University of Minnesota acknowledge the UMCC as an exceptionally successful matrix organization in a large public research university, and are pledged to work aggressively to help it achieve its goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA077598-13S2
Application #
8325757
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-06-01
Project End
2014-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
13
Fiscal Year
2011
Total Cost
$75,000
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Lassig, Amy Anne D; Bechtold, Joan E; Lindgren, Bruce R et al. (2018) Tobacco exposure and wound healing in head and neck surgical wounds. Laryngoscope 128:618-625
Petzel, Sue V; Isaksson Vogel, Rachel; Cragg, Julie et al. (2018) Effects of web-based instruction and patient preferences on patient-reported outcomes and learning for women with advanced ovarian cancer: A randomized controlled trial. J Psychosoc Oncol 36:503-519
Pierpont, Elizabeth I; McCoy, Erin; King, Kelly E et al. (2018) Post-transplant adaptive function in childhood cerebral adrenoleukodystrophy. Ann Clin Transl Neurol 5:252-261
Passow, Kellan T; Harki, Daniel A (2018) 4-Cyanoindole-2'-deoxyribonucleoside (4CIN): A Universal Fluorescent Nucleoside Analogue. Org Lett 20:4310-4313
Guo, Zhijun; Johnson, Veronica; Barrera, Jaime et al. (2018) Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them. Cancer Metastasis Rev 37:409-423
Scott, Milcah C; Temiz, Nuri A; Sarver, Anne E et al. (2018) Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma. Cancer Res 78:326-337
Ho, Yen-Yi; Nhu Vo, Tien; Chu, Haitao et al. (2018) A Bayesian hierarchical model for demand curve analysis. Stat Methods Med Res 27:2038-2049
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
How, Joan; Vij, Kiran R; Ebadi, Maryam et al. (2018) Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 93:E381-E383
Ustun, C; Brunstein, C; DeFor, T et al. (2018) Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. Bone Marrow Transplant 53:97-100

Showing the most recent 10 out of 1013 publications